1 Compensation and Insurance for Participants/ Subjects Harmed in Clinical Research Studies: Process of the Inheritance of Good Clinical Practice (GCP) in Japan and its Present Status WMA Expert Conference on the Declaration of Helsinki February28-March1,2013, Tokyo,Japan Tatsuo Kuroyanagi Attorney-at-Law; Legal Advisor Japan Medical Association
4 Revision of the third sentence of paragraph14 of the DoH at Seoul in 2008 The protocol should include provisions for treating and/or compensating subjects who are harmed as a consequence of participation in the research study. Guaranteeing (free) treatment and compensation for loss to subjects who are harmed is at the core of the protection of subjects, and this provision needs to be strengthened further in the future.
5 Experience of numerous large lawsuits brought by victims of drug-induced suffering against pharmaceutical companies, physicians, and the national government Thalidomide Streptomycin (SM) hearing loss and shock death SMON (subacute myelo-optic neuropathy) caused by chinoform (clioquinol) Quadriceps and other muscle contracture resulting from intramuscular injection of chloramphenicol, etc., in infants Chloroquine retinopathy
6 Changes in the Pharmaceutical Affairs Act in Japan, etc. 1960: (New) Pharmaceutical Affairs Act enacted 1961: Universal health insurance coverage launched 1964: WMA DoH adopted 1971: Drug efficacy reevaluation system introduced; sale of Dihydro SM and Compound SM suspended 1975: Revisions to WMA DoH adopted in Tokyo
7 Changes in the Pharmaceutical Affairs Act in Japan, etc. 1977: Judge Kabe of the Tokyo District Court issued a settlement proposal in the SMON case. 1979: Major revision of the Pharmaceutical Affairs Act; Adverse Drug Reaction Sufferings Relief Fund Law enacted 1989: Good Clinical Practice for Trials on Drugs (Notification) issued by the Director of Pharmaceutical Affairs Bureau, Ministry of Health and Welfare of Japan 1990: Manual of Good Clinical Practice (GCP) for Trials on Drugs published
8 Origin of Japanese GCP In 1989, the Ministry of Health and Welfare of Japan added the subtitle GCP to the Japanese title for the Good Clinical Practice for Trials on Drugs (Notification). That most likely originated with the EC s (at the time) Good Clinical Practice for Trials on Medicinal Products in the European Community (1989). When the above guidelines were announced, the final draft of the EC GCP and the text (in English) of France s GCP were introduced alongside of the DoH revised at Venice in 1983, FDA regulations (U.S.A.)
9 Origin of Japanese GCP Declara4on of Helsinki France s GCP EC GCP (1989) FDA regula4ons 1989 Japanese GCP(No4fica4on) 1996 ICH- GCP 1997 Japanese GCP(Ministerial Ordinance )
10 Changes in the GCP system (1) from administrative guidance to a legal system 1983: Work began on preparing the Japanese GCP Oct. 1989: Good Clinical Practice for Trials on Drugs (Notification) Apr. 1990: Manual of Good Clinical Practice (GCP) for Trials on Drugs published Apr. 1990: Japan, together with the EU and the US, participates in the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use
11 Changes in the GCP system (2) from administrative guidance to a legal system Jul. 1995: Product Liability Act went into force May 1996: ICH-GCP Yokohama Accord Oct. 1996: DoH Somerset West revision (placebo provisions) Mar.1997: Japanese Ministerial Ordinance on Good Clinical Practice for Drugs May1997: About Application of Good Clinical Practice for Drugs Content of Good Clinical Practice (GCP) for Drugs 1998: Full implementation of new GCP
12 Inclusion of the GCP system in the Pharmaceutical Affairs Act and establishment of the compensation system for health damage 1989 GCP standards when conducting clinical studies (trials) subject to Pharmaceutical Affairs Act, the sponsor was requested (administrative guidance) to take steps to provide compensation and insurance for subjects, and interested parties followed those requests. It became essential to insert in consent forms and explanatory statements provisions for treatment and compensation in the event a subject s health is damaged.
13 Inclusion of the GCP system in the Pharmaceutical Affairs Act and establishment of the compensation system for health damage Based on the above provisions, interested parties promised (free) treatment and compensation and, at the same time, requested non-life insurance companies to create indemnity insurance policies that they then took out. The GCP ministerial ordinance of 1997 is based on law and the compensation system for health damage was elevated to a legal system. However, it is just a general framework with no definite details spelled out for the compensation system.
14 Typical example of a treatment and compensation for health damage provision The following is an example of a treatment and compensation for health damage provision: Please consult your primary doctor immediately if you develop symptoms during this trial that you did not have before. Appropriate treatment and appropriate measures shall be taken if you suffer an adverse effect or other health damage during or after participation in this trial. You may also receive compensation according to the type and degree of health damage. However, please be aware that you may not receive compensation if it is found that you did not follow your primary doctor s instructions or that the health damage was due to your own carelessness.
15 Present status of the compensation system Japan has developed a compensation system that covers a victim s loss to a certain limit in exchange for not requiring proof of negligence, with the aim of providing relief for the victim, apart from tort liability that questions negligence and provides indemnity for gross damages. Occupational accidents are one example, which have a compensation system based on the Industrial Accident Compensation Insurance Act. As a rule of thumb, this system determines the amount to be paid (compensation) by removing consolation money from the gross damages items, dividing the degree of harm (loss of capacity to work = after effect) into 14 levels (grades), and taking the grade into consideration, with average wages as the base. This is the model for many compensation systems (the Automobile Liability Security Act uses the above occupational accident compensation system in certification of after effects impediment).
16 Present Status of the Compensation System Even now there is an adverse drug reaction relief system for marketed drugs. The problem is that, even though the times have changed since the system was developed the system still excludes anticancer and carcinostatic drugs from coverage and discards victims with grade 7 or below injuries for occupational accidents (traffic accidents).
17 Present status of the compensation system Two compensation systems Trials in which healthy individual participate (Phase I): A system that handles compensation according to the occupational accident compensation system was established by the later period of the old GCP age and has lasted up to the present. Trials in which patients participate (Phase II and III): Many pharmaceutical companies proposed to pay in conformity with the compensation system of the adverse drug reaction relief method. The reporter is against this.
18 Present status of compensation insurance(1) At present, pharmaceutical companies that conduct trials based on the Pharmaceutical Affairs Act invariably take out liability insurance covering compensation for loss up to the highest amounts of compensation provided by the occupational accident compensation system and the adverse drug reaction relief system, respectively. This is because they are required to submit the proposed subject consent and information sheet and the certificate of insurance coverage issued by an insurance company to the institutional review board. Examples of three types of are shown at the next slide.
19 Present status of compensation insurance(1) A. Comprehensive Liability Insurance Certificate of Insurance Coverage Period: 1 st March, st March, 2014 Covered Perils Comprehensive General Liability 1),2) Products,3) Fire Legal, 6) Clinical Testing Liability and Experimental Testing of New Drugs Endorsement/Compensation in Clinical Trials Endorsement (The Indemnity provided by this policy shall apply to legal liability and compensation for bodily injury to third parties in clinical trials conducted by or on behalf of the Insured.) Limit of Liability;
20 Present status of compensation insurance (2) B. Healthy Subject Compensation Insurance Certificate of Product Liability Insurance Coverage (Schedule) Insured: ABC Co., Ltd. Term: Midnight on 1 st April 2013 to Midnight on 31 st March 2014 Amount payable: Bodily injury liability per person: 100 million yen; per accident: 300 million yen(3.2 million USD)*; during the insurance term: 300 million yen Deductible: Per accident: 500,000 yen(5,263 USD) Notes: Clinical Trial Liability Insurance Rider Per accident, during insurance term: 300 million yen (coverage for bodily Injury liability per accident, payment within the limit during the insurance term) Coverage limit per victim: as shown on reverse (no exemption from responsibility) 25 th February 2013 Fire Insurance Company *US dollar/jpy exchange rate: US$1 95 yen
21 Present status of compensation insurance(3) B. Reverse Coverage limit per subject Degree of health damage: trial on healthy individuals Payment limit (per subject) Death: 30 million yen(0.3 million USD) After effects impediment grade 1: 90 million yen (0.9 million USD) After effects impediment grade 2: 90 million yen (0.9 million USD) After effects impediment grade 3: 70 million yen (0.7 million USD) After effects impediment grade 4: 65 million yen (0.7 million USD) After effects impediment grade 5: 55 million yen (0.6 million USD) After effects impediment grade 6: 50 million yen (0.5 million USD) After effects impediment grade 7: 40 million yen (0.4 million USD) After effects impediment grade 8: 32 million yen (0.3 million USD) After effects impediment grade 9: 25 million yen (0.3 million USD) After effects impediment grade 10: 20 million yen (0.2 million USD) After effects impediment grade 11: 15 million yen (0.2 million USD) After effects impediment grade 12: 10 million yen (0.1 million USD) After effects impediment grade 13: 7 million yen (0.1 million USD) After effects impediment grade 14: 4 million yen (42,105 USD) Lost work time compensation payment: 13,000 yen (137 USD) per subject per day for the period beginning on the fourth day of no wages due to lost work time
22 Present status of compensation insurance (4) C.Patient Subject Compensation Insurance Certificate of Product Liability Insurance Coverage Policy Owner: XYZ Co., Ltd. Insured: XYZ Co., Ltd. Term: Midnight on 1 st January 2013 to Midnight on 31 st December 2015 Coverage limit: Bodily injury liability per person: 100 million yen (1.1 million USD) ; per accident: 500 million yen (5.3 million USD); during the insurance term: 500 million yen Deductible: Bodily injury liability per accident: 1 million yen (10,526 USD) Notes: Investigational drug code: PP-001; investigation drug rider ancillary; clinical trial compensation liability insurance ride ancillary Death: 20 million yen (0.2 million USD) After effects impediment grade 1: 70 million yen (0.7 million USD) After effects impediment grade 2: 50 million yen (0.5 million USD) 25 th November 2012 ZZZ Marine Insurance Company Reporter note: Since after effects impediment grades 1 and 2 are the only ones covered by the insurance, it is clear that only compensation equivalent to the adverse drug reaction compensation system is being considered.
23 Compensation for clinical research besides trials Ethical Guidelines on Clinical Research (1) ICH-GCP (6) does not distinguish between clinical trial studies subject to the Pharmaceutical Affairs Act and other clinical research. The government requires interested parties to comply with the GCP ministerial ordinance of 1997, limited to studies subject to the Pharmaceutical Affairs Act, but it has done nothing to develop standards relating to clinical research not covered by the Pharmaceutical Affairs Act. On July 30, 2003, the Japanese Ministry of Health and Welfare established Ethical Guidelines on Clinical Research, but they are nothing more than administrative measures. These guidelines went through a major revision of DOH in 2008 and have come down to the present.
24 Compensation for clinical research besides trials Ethical Guidelines on Clinical Research (1) Statements regarding compensation for subjects were apparently strengthened during the 2008 revision. The heads, etc., of clinical research organizations are required to take out insurance and take other necessary measures for compensation for health damage to subjects, and to sufficiently explain beforehand the content of insurance and other necessary measures for compensation for health damage and obtain subjects consent.
25 Compensation for clinical research besides trials Ethical Guidelines on Clinical Research (2) However, with the provision that, the existence or non-existence of compensation for health damage to subjects associated with the conduct of the clinical research must be indicated in the clinical research protocol, if it is indicated that compensation will not be provided and the subjects consent is obtained, compensation is not needed. Further, by expressing the view that, Other necessary measures refers to things such as the provision of medical care for health damage or the provision of other services, it pulls down with its own hands the foundation of the basic principles built at the beginning.
26 Compensation for clinical research besides trials (present status 1) Research besides clinical research subject to the Pharmaceutical Affairs Act is mainly conducted by university hospitals and national, public, or other large medical institutions. In recent years, a variety of clinical research has been conducted jointly by multiple institutions (and sometimes even with institutions in other countries).
27 Compensation for clinical research besides trials (present status 1) Restricting our conversation to research in Japan, the biggest financer or aid provider for research funding for these studies is most likely the national government. The problem is that aid is not always sufficient, and researchers are forced to conduct research with minimal outlays. As a result, the reality is that even if there is a need, they cannot take out insurance to cover compensation. This results in a situation where clinical research despite being cutting-edge research continues unreservedly without compensation.
28 Compensation for clinical research besides trials (present status 2) The following is an example use by an organization called JCOG. There is a possibility of developing unforeseen serious complications or other health damage during or after completion of participation in this clinical study. In that case, appropriate responses will be taken, the same as with treatment for health damage in usual medical care. However, the medical expenses shall be borne by the patient, since the treatment will be provided as health-care services provided under health insurance, the same as usual treatment. If you feel some kind of health damage that does not occur during usual treatment, as a result of participation in this clinical study, inform your doctor without reservation. Also note that no sympathy money, other type of benefit, or any kind of special financial compensation has been prepared for health damage sustain in this clinical study. Reporter note: JOCG (Japan Clinical Oncology Group) is a research organization run partially with research funding of an Oncology Grantin-Aid from the Ministry of Health, Labour and Welfare and partially with a Health and Labour Sciences Research Grant called a Grant for the Third-Term Comprehensive 10-Year Strategy for Cancer Control. It consists of 13 specialty study groups and enjoys the participation of nearly 200 hospitals across Japan.
29 Compensation and insurance for clinical research besides trials A lot of clinical research not covered by the Pharmaceutical Affairs Act is conducted in many education-related hospitals such as university hospitals, and recently regulatory agencies have started to provide strong direction to take out compensation insurance. As a result, researchers are hoping to take out insurance, but with little understanding on the part of interested parties, the reality is that there is not even a form in place, as compared to trials that have only just gotten underway. The legislation of guidelines with solid content needs to take place as soon as possible, the same as with pharmaceuticals, in order to realize the principles of the ICH-GCP, which aimed for substantial championship of subjects. This is an urgent issue to be resolved that has been left before us.
30 Conclusion I attempted to put the current status of today s issues in Japan into a figure to wrap up today s report.
31 Subject to Subjects Conclusion GCP ministerial ordinance Clinical studies (trials) covered by the Pharmaceu:cal Affairs Act Health individuals Pa:ents Ethical guidelines on clinical research Other clinical studies Health individuals/ pa:ents Compensa:on Yes Yes Provision exists, but without compensa:on accepted Content/ degree Similar to the occupa:onal accident relief system (grade 1 to grade 14) Similar to the adverse drug reac:on relief system (excludes grades 8 and below from the occupa:onal accident system and an:cancer drugs) Actual condi:on is chao:c Backed up by insurance Yes Yes Insufficient/ undeveloped Type of insurance Treatment Treatment only only Combined with product liability insurance, etc. Combined with product liability insurance, etc.
Research and Reviews Compensation and Insurance for Participants/Subjects Harmed in Clinical Research Studies: Process of the inheritance of Good Clinical Practice (GCP) in Japan and its present status
History and Principles of Good Clinical Practice Cristina E. Torres, Ph.D. Social Science Professor, UPM-NIH FERCAP Coordinator ICH: International Conference on Harmonization GCP: Good Clinical Practices
EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE Purpose 1. The Clinical Trials Directive 2001/20/EC heralds certain additional responsibilities for the Medicines and Healthcare
BOARD OF INVESTMENT Clinical Research in Mauritius This document provides an informative summary of the procedure to apply for a clinical research protocol in Mauritius. Contents INTRODUCTION... 2 I. APPLICATION
Clinical Trial Compensation Guidelines Preface These guidelines contain two distinct sections: Phase I Clinical Trials Compensation Guidelines Phases II, III and IV Clinical Trials Compensation Guidelines
Public Policy Statement: Clinical Trial Ethics Purpose As a global healthcare company, Merck's role is first and foremost to discover, develop and provide innovative products and services that save and
WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Medical Research Involving Human Subjects Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by
REGULATORY MANAGER Comparing GCP Requirements for Medical Device Clinical Trials in the US and Japan By Harmonization-by-Doing Working Group 4 Introduction The convergence of US and Japanese medical device
Good Clinical Practice 101: An Introduction Presented by: Lester Jao Lacorte, MD Medical Officer Commissioner s Fellow Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological
20 & 21 October 2005 Clinical trials Risk issues within a wider Europe Adrien Collovray Life Science Conference 2005 Berlin, Germany Clinical trials EC Directive on clinical trials Insurance Requirements
The English version of this Decree was prepared in order to help comprehension by non- Italian mother tongue users, but it is NOT an official document. Please, refer to the Italian version for the only
Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015 Clinical Trials at HKU Phase 1 Phase II Phase III Phase IV Conducted on patient
JMA Policies Professional Liability Insurance Program of the Japan Medical Association JMAJ 50(5): 390 396, 2007 Katsuyuki KINOSHITA* 1 Introduction The shortage of physicians has become a social issue
RESEARCH INVOLVING HUMAN SUBJECTS GUIDELINES FOR IRBS EXECUTIVE SUMMARY Principle 1. There is general agreement internationally that human biomedical research involving risk of harm to human subjects should
AUTOMOBILE LIABILITY SECURITY ACT & RELATED CABINET ORDER, MINISTERIAL ORDINANCE AND NOTIFICATION Including: Policy Conditions for Automobile Liability Insurance As of May 2, 2011 Translated and published
Block Insurance Policy for Public Liability, Employees Compensation and Group Personal Accident 1999/2000, 2000/2001 and 2001/2002 School Years Ref. : ED(SCH)I/10/88 EDUCATION DEPARTMENT HONG KONG ADMINISTRATION
Update to your Vero MotorPlan policy As a result of a change brought about by the Sentencing Amendment Act 2014, we would like to bring to your attention an update to our Vero MotorPlan policy wording.
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Estonia Question 1: What laws or regulations apply to an application for conducting a clinical
IRB POLICY ON HUMAN RESEARCH PROTECTION (HRP) AND GOOD CLINICAL PRACTICE (GCP) TRAINING Collaborative Institutional Training Initiative (CITI) Requirements at Adventist Healthcare, Inc. I. Required Human
Managing Risk in Clinical Research Dr Martha J Wrigley R&D Manager Senior Visiting Fellow University of Surrey Aim of the session To explore the risks associated with clinical research and understand how
Serial 137 Personal Injuries (Civil Claims) Bill 2003 Dr Toyne A BILL for AN ACT to provide for the economical and early resolution of claims for damages for personal injuries before proceedings are commenced,
Tip Sheet 11: Following the Guideline of the International Conference on Harmonization Good Clinical Practice (E6) Related Accreditation Elements: I.1.D., I.1.F., I-2, I.7.B., II.2.E., II.2.F., II.4.A.,
Bill No. 18/11. Work Injury Compensation (Amendment) Bill Read the first time on 17th October 11. A BILL intituled An Act to amend the Work Injury Compensation Act (Chapter 34 of the 09 Revised Edition).
Amended Pharmaceutical Affairs Law and Regenerative Medicine 19 th June 2014 International Regulatory Science Symposium Shinji MIYAKE, Ph.D. Professor, Keio Center for Clinical Research, School of Medicine,
CLINICAL TRIAL LIABILITY INSURANCE - R.Qaiser, Faculty Member, NIA, Pune With the opening of insurance sector and the demise of tariff regime, suddenly the Competition has become very fierce and we are
WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended by the: 29th WMA General
Florida Clinical Trials Agreement Agreement to Reduce Cancer Morbidity and Mortality in Florida The undersigned parties to this Florida Clinical Trials Agreement (Agreement) acknowledge that Florida ranks
UK Implementation of the EU Clinical Trial Directive 2001/20/EC: GCP Aspects. Dr. Colin Wilsher, FRQA. BARQA GCP Committee Chairman; & Pfizer Worldwide Development Quality Assurance. GIQAR, Roma, October
QUESTION NO. 3 Amendment to Titles 1 and 3 of the Nevada Revised Statutes CONDENSATION (ballot question) Shall Title 1 of the Nevada Revised Statutes governing attorneys, and Title 3 of the Nevada Revised
Guest Voluntary Settlement Coverage By Darrell Hyde Before discussing Guest Voluntary Settlement Coverage (GVS) it would be helpful to review the basic concept of liability insurance. The purpose of liability
Overview of NICA Insurance Policy Clubs: General Liability (includes coverage for trail maintenance and repair by the club. Club rides, training rides/races and other club functions such as meetings and
Investigator Responsibilities Standard Operating Procedure Office of Health and Medical Research Queensland Health SOP reference: 010 Version number: 1 Effective date: 01 June 2010 Review due: May 2011
Clinical evaluation Latest development in expectations EU and USA Medical Devices: staying ahead of regulatory developments Gert Bos BSI Israel 22 April - Herzliya Copyright 2012 BSI. All rights reserved.
Auto Insurance Buyers Guide Table of Contents Understand Your Rights as a Consumer...1 Introduction...... 2 Why You Need Auto Insurance...... 3 When to Shop for a New Auto Insurance Policy.. 4 How to Shop
Short Term Disability Income Protection Plan Effective Date: January 1, 2012 Contact Information Plan Administrator: Address and Telephone #: AOL Inc. 22000 AOL Way Dulles, VA 20166 703-265-1968 703-265-3981
International Clinical Trials: Global Compliance Norms The Declaration of Helsinki John R. Williams, Ph.D. University of Ottawa, Canada II International Pharmaceutical Regulatory and Compliance Congress
Staker Parson Short Term Disability Income Protection Plan Effective Date: 01/01/2006 Contact Information Plan Administrator: Address and Telephone #: Claims Administrator: Address and Telephone #: Staker
The Clinical Trials Directive in the EU: Present and Future Elisabethann Wright, Partner Maurits Lugard, Partner May 2010 Background (1) The Clinical Trials Directive 2001/20/EC The intention of this Directive
The Changing Regulatory Requirements for Applied Human Pharmacology Thomas Sudhop Federal Institute for Drugs and Medical Devices (BfArM) What was first The Regulatory Past Rules for Marketing Authorisation
Memorial Hermann Employer Occupational Accident Program Houston, Texas Memorial Hermann Health Solutions, Inc. Employer Occupational Accident Program Insurance underwritten by ACE American Insurance Company
rightlawyers.com RIGHT Lawyers Right Lawyers has successfully represented numerous clients in the areas of car accidents, work injuries, and slip and falls. The goal of this guide is to provide you answers
Drug Development in Japan A Clinical View Ken Takeshita, M.D. Formerly, Chief Medical Officer and Head, Research and Development, Celgene KK (Japan) Currently, Senior Director, Celgene Corp (USA) Disclaimer
Short Term Disability Income Protection Plan Effective Date: January 1, 2011 Contact Information Plan Administrator: TIB - The Independent Bankers Bank Address and Telephone #: 350 Phelps Drive Irving,
Your Rights Under the Missouri Workers Compensation Law All states have workers compensation laws. The Missouri Workers Compensation Law is contained in Chapter 287 of the Revised Statutes of Missouri.
Chemicals and Life Sciences Industry Practice Insurance and compensation in the event of injury in Phase I clinical trials in the United Kingdom i Insurance and compensation in the event of injury in Phase
Overview of NICA Insurance Policy National Interscholastic Cycling Association 2414 Sixth Street Berkeley CA 94710 (510) 524-5464 www.nationalmtb.org Clubs: General Liability (Includes coverage for Trail
Pharmaceuticals and Medical Devices Agency, Japan Fiscal Year 2010 Greetings Outline of the Pharmaceuticals and Medical Devices Agency (PMDA) Services of PMDA Relief Services for Adverse Health Effects
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials
This document is made available electronically by the Minnesota Legislative Reference Library as part of an ongoing digital archiving project. http://www.leg.state.mn.us/lrl/lrl.asp.~l' ''''d:.,j i.;'~\;
Negotiating Clinical Trial Agreements: The Hospital s Perspective P R E S E N T E D B Y: David Vukadinovich, JD, MPH Senior Counsel HCCA Research Compliance Conference October 20, 2009 Minneapolis Presentation
Overview of the Healthcare Policy Introduction For Japan, which is becoming an ultra-aging society ahead of other countries, it is important to realize the world s most advanced medical technologies and
XIII Chronology Year 1859 1867 1869 1873 1877 1878 1879 1883 1887 1888 1893 1895 1898 1899 1900 1904 1907 1910 1911 1914 Non-life insurance business was started in Yokohama by a foreign insurance company.
Changing Tort Reform In Kentucky Christel Siglock By changing its current No-Fault and Tort law options, Kentucky could; 1) Reduce the number of lawsuits filed, 2) Thus reducing insurance company payouts
Cooper Hurley Injury Lawyers 2014 Granby Street, Suite 200 Norfolk, VA, 23517 (757) 455-0077 (866) 455-6657 (Toll Free) YOUR RIGHTS WHEN YOU ARE INJURED ON THE RAILROAD Cooper Hurley Injury Lawyers 2014
Ministry of Social Affairs and Health, Finland N.B. Unofficial translation, legally binding only in Finnish and Swedish No. 1383/2001 Occupational Health Care Act Issued in Helsinki on 21 December 2001
NHS Central Midlands Commissioning Support Unit Birmingham CrossCity Clinical Commissioning Group NHS Birmingham South Central Clinical Commissioning Group NHS Solihull Clinical Commissioning Group NHS
FOREIIGN WORKERS ((Prrohiibiittiion off unllawffull emplloymentt and assurrance off ffaiirr condiittiions)) LAW,, 5751--1991 Chapter one: Definitions 1. In this law - Foreign worker - worker who is not
We are pleased to enclose a claim form as requested. PERSONAL ACCIDENT AND/OR SICKNESS CLAIM FORM Most delays in settling claims arise because claim forms are not fully completed or requested documents
October 5, 2011 Remaining Changes to Alberta s Insurance Act to Come into Force on July 1, 2012 Parlee McLaws LLP Although the Insurance Amendment Act, 2008, which contains important changes to Alberta
Oversight of Clinical Trials in Europe - Member State perspective Gunnar Danielsson Senior Expert Pharmaceutical Inspector Oversight of Clinical Trials Oversight of clinical trials occur on many different
Step-by-step guide to pursuing a medical negligence claim Suffering from medical negligence can be a painful and distressing experience for anyone. This short guide offers some advice to help people thinking
Act on Asbestos Health Damage Relief Table of Contents Chapter 1 General Provisions (Articles 1 and 2) Chapter 2 Relief Benefit Section 1 Payment, etc. (Articles 3 to 30) Section 2 Expense Subsection 1
OVERVIEW OF HNO, PHYSICAL DAMAGE, CASE STUDY Presented by: Alliant Insurance Session Overview At the end of this presentation, participants should be able to: 1. Define what HNO means 2. Understand how
Motor Vehicle Accident Claims: What are your rights? If you or a loved one has been seriously injured in a motor vehicle accident, there are a number of critical decisions that must be made. Who will care
For more information please visit Strategic Capital Corporation at www.strategiccapital.com, or contact us at Toll Free: 1-866-256-0088 or email us at firstname.lastname@example.org. ANNOTATED LAWS OF MASSACHUSETTS
LONG-TERM DISABILITY BENEFITS Revised September 1, 2004 No. 6 (*) 7000CI-U-EZ E O BENEFIT INFORMATION WHY LONG-TERM DISABILITY COVERAGE People tend to take their good health and ability to work for granted.
Frequ quentl tly asked questio tions Low Value Personal Injury Claims in Road Traffic Accidents Stage 1 General Q1. When will the Rules be drafted and ready? A1. The Civil Procedure Rule Committee approved
Clinical Trials: Questions and Answers Key Points Clinical trials are research studies that test how well new medical approaches work in people (see Question 1). Every clinical trial has a protocol, which
These guidelines apply to all research projects where human subjects are involved in the study GUIDELINES FOR RESEARCHERS PATIENT INFORMATION SHEET & CONSENT FORM The guidance, which follows, applies primarily
Information for members I-04-63 Suggested distribution Vice-Chancellors and Principals, Pro Vice- Chancellors (Research), University Registrars and Secretaries, Directors of Human Resources, Deans/Heads
Motor Vehicles (Third-Party Risks and Compensation) (Amendment) Bill Bill No. 18/2013. Read the first time on 21st October 2013. A BILL intituled An Act to amend the Motor Vehicles (Third Party Risks and
Revisions on the Declaration of Helsinki Prof. J. Mfutso-Bengo, PhD Center of Bioethics (CEBESA) University of Malawi College of Medicine Cape Town South Africa December 2012 www.medcol.mw Josephemail@example.com
MOTOR VEHICLE ACCIDENT CLAIMS ACT Act 198 of 1965 AN ACT providing for the establishment, maintenance and administration of a motor vehicle accident claims fund for the payment of damages for injury to
Class Notice of Proposed Settlement IN THE MONTANA EIGHTH JUDICIAL DISTRICT COURT, CASCADE COUNTY If Allstate Paid You for an Automobile Bodily Injury Claim, You May Be Entitled to Money from a Proposed
PERSONAL INJURY COMPENSATION CLAIM GUIDE PERSONAL INJURY COMPENSATION CLAIM GUIDE This booklet has been produced by D.J. Synnott Solicitors to give our clients an understanding of the personal injury compensation
Terms and Conditions of International Money Transfer Transactions by Card Members (For City Express) When using the Card International Money Transfer Service for Card Members provided by SBI Remit Co.,
MAKING A PERSONAL INJURIES CLAIM* GETTING STARTED DO I HAVE A CASE? The first step is to contact one of our experienced personal injuries solicitors and arrange a no obligation consultation. At the initial
DEVELOPMENTS IN 2008 LEGISLATION & TREATIES 73 Editorial Notes: Traditional criminal trials leave laymen and victims out in the cold, while today the participation of both in criminal trials leads to the
Short Term Disability Income Protection Plan Effective Date: January, 1, 2015 Contact Information Plan Administrator: Address and Telephone #: Prime Therapeutics, LLC 1305 Corporate Center Drive Eagan,
Research and Reviews Conflicts between Public Car Insurance and Public Medical Insurance in Japan: International Comparison Survey JMAJ 57(2): 93-103, 2014 Kazuki SAKAGUCHI, 1 Koichiro MORI 1,2 Abstract